Herein, we demonstrate that dichloromethanol but not difluoromethanol is a viable surrogate of carbon monoxide for prodrug design. A proof of concept was established by the successful development of a ROS-responsive carbon monoxide prodrug, presenting specific CO release in response to endogenous ROS in cells.